文献速递消化系统肿瘤

帕博利珠单抗治疗难治性MSI-H/dMMR转移性结直肠癌的II期开放标签研究:KEYNOTE-164

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
PubMed 文献 · J Clin Oncol · 2019-11-14

KEYNOTE-164是一项全球多中心II期开放标签研究,评估帕博利珠单抗在经治的MSI-H/dMMR转移性结直肠癌患者中的抗肿瘤活性。共纳入124例患者(队列A 61例,队列B 63例),客观缓解率均为33%,中位缓解持续时间未达到,安全性可控。

要点

  • 帕博利珠单抗在经治MSI-H/dMMR转移性结直肠癌中客观缓解率为33%。
  • 两个队列中位缓解持续时间均未达到,中位总生存分别为31.4个月和未达到。
  • 治疗相关3-4级不良事件发生率分别为16%和13%,安全性可控。

核心结论

  • 帕博利珠单抗在经治的MSI-H/dMMR转移性结直肠癌患者中有效且安全性可控。

研究设计与样本

  • II期开放标签研究,全球128个中心参与,纳入124例MSI-H/dMMR转移性结直肠癌患者。
  • 队列A为接受≥2线标准治疗(包括氟嘧啶、奥沙利铂和伊立替康,联合或不联合抗VEGF/EGFR单抗)的患者,共61例。
  • 队列B为接受≥1线治疗的患者,共63例。
  • 患者每3周接受帕博利珠单抗200 mg,最长2年,直至疾病进展、不可接受毒性或退出。
  • 主要终点为独立中心审查根据RECIST v1.1评估的客观缓解率。

主要发现

  • 队列A中位随访31.3个月(范围0.2-35.6个月),队列B中位随访24.2个月(范围0.1-27.1个月)。
  • 队列A客观缓解率为33%(95% CI 21%-46%),队列B为33%(95% CI 22%-46%)。
  • 两个队列中位缓解持续时间均未达到。
  • 队列A中位无进展生存期为2.3个月(95% CI 2.1-8.1个月),队列B为4.1个月(95% CI 2.1-18.9个月)。
  • 队列A中位总生存期为31.4个月(95% CI 21.4个月-未达到),队列B为未达到(95% CI 19.2个月-未达到)。

关键数值与推荐

  • 队列A治疗相关3-4级不良事件发生于10例(16%)患者,队列B为8例(13%)。
  • 队列A中最常见的≥2例患者发生的3-4级不良事件为胰腺炎、疲乏、丙氨酸氨基转移酶升高和脂肪酶升高(各2例,3%)。

临床怎么用

  • 对于经治的MSI-H/dMMR转移性结直肠癌患者,帕博利珠单抗可作为治疗选择。
  • 治疗期间需监测免疫相关不良事件,如胰腺炎、疲乏和肝酶升高。

局限性

  • 本研究为II期单臂开放标签研究,无随机对照。
  • MSI-H/dMMR状态在当地评估,未集中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC). METHODS: This phase II open-label study involved 128 centers worldwide. Eligible patients were age ≥ 18 years and had metastatic MSI-H/dMMR CRC treated with ≥ 2 prior lines of standard therapy, including fluoropyrimidine, oxaliplatin, and irinotecan with or without anti-vascular endothelial growth factor/epidermal growth factor receptor monoclonal antibody (cohort A) or ≥ 1 prior line of therapy (cohort B). MSI-H/dMMR status was assessed locally. Patients received pembrolizumab 200 mg every 3 weeks for up to 2 years until progression, unacceptable toxicity, or withdrawal. The primary end point was objective response rate by RECIST version 1.1 by independent central review. Secondary end points were duration of response, progression-free survival (PFS), overall survival, safety, and tolerability. RESULTS: A total of 124 patients with MSI-H/dMMR CRC (61 in cohort A, 63 in cohort B) enrolled. At data cutoff, median follow-up was 31.3 months (range, 0.2-35.6 months) for cohort A and 24.2 months (range, 0.1-27.1 months) for cohort B. Objective response rate was 33% (95% CI, 21% to 46%) and 33% (95% CI, 22% to 46%), respectively, with median duration of response not reached in either cohort. Median PFS was 2.3 months (95% CI, 2.1 to 8.1 months) and 4.1 months (95% CI, 2.1 to 18.9 months). Median overall survival was 31.4 months (95% CI, 21.4 months to not reached) and not reached (95% CI, 19.2 months to not reached). Treatment-related grade 3-4 adverse events occurred in 10 patients (16%) in cohort A and 8 (13%) in cohort B, with the most common occurring in ≥ 2 patients being pancreatitis, fatigue, increased alanine aminotransferase, and increased lipase (2 patients each; 3%) in cohort A. CONCLUSION: Pembrolizumab is effective with a manageable safety profile in patients with MSI-H/dMMR CRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2019. PMID: 31725351. doi:10.1200/JCO.19.02107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。